Radioimmunotherapy for B-cell non-hodgkin lymphomas. - Wikidata - wikimedia - TriplyDB

Radioimmunotherapy for B-cell non-hodgkin lymphomas.

Radioimmunotherapy for B-cell non-hodgkin lymphomas.

http://www.wikidata.org/entity/Q38019790

about

New antibody approaches to lymphoma therapy Evaluation of Acridine Orange Derivatives as DNA-Targeted Radiopharmaceuticals for Auger Therapy: Influence of the Radionuclide and Distance to DNA Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.Dosimetric analysis of (123)I, (125)I and (131)I in thyroid follicle models.Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo.Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction.An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Radiofrequency ablation before intratumoral injection of (131)I-chTNT improves the tumor-to-normal tissue ratio in solid VX2 tumor.The new golden era for radioimmunotherapy: not just for lymphomas anymore.The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.

P2860

Q27022373-435576EE-1AF7-4CC9-A582-3D3503CB5504 Q31162976-1A4B95CA-E77E-4F61-9524-0A8E575A5BC4 Q33413834-0CB6A9AA-C13A-4FC4-9971-FE02CBABC9E1 Q33690142-0A81F84F-BCA5-4317-8140-ACBD620B6F78 Q33833023-B2008A69-6AA8-4F04-AD55-4FD32BF01025 Q34463593-CB0D18E5-DCFD-4EB0-883A-0B07A0456DE4 Q35161396-C4D5B295-1726-479A-B46B-A64C8F6B2EC1 Q35670632-819E821B-9273-4412-AE4E-40AE63E1639A Q36437102-D9E847C9-2485-4C53-8C01-93448542A725 Q36979140-E083F673-2945-4EDF-BF58-054737C79540 Q37323292-6192DA0A-88E4-4918-BED5-AB652B17AF55 Q38072815-54DFD1E6-BF2C-48DA-8FB2-80F22D545617 Q47563526-041C1619-27DF-4A85-8E45-D0EDE58C1390

P2860

Radioimmunotherapy for B-cell non-hodgkin lymphomas.

http://www.wikidata.org/entity/Q38019790

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Radioimmunotherapy for B-cell non-hodgkin lymphomas.

@en

type

label

Radioimmunotherapy for B-cell non-hodgkin lymphomas.

@en

prefLabel

Radioimmunotherapy for B-cell non-hodgkin lymphomas.

@en

P1433

Q38019790-81F83C83-068F-47BD-ABAF-BA0AC611D61D

P1476

Q38019790-8B221166-C837-4612-B6FD-3180967C96E3

P2093

Q38019790-45F536D0-6AEC-4FBB-9A48-A5443FC6EA4C

P2860

Q38019790-03E07334-4D60-41D6-94D1-E3AC9409075F

Q38019790-075BA439-447A-4D0E-A339-43C150476FE5

Q38019790-1CB35F0A-9982-49F3-9387-41BE7EDEDDFE

Q38019790-1D6734C1-D1C2-49F5-82D2-8AB1E39537D9

Q38019790-297B70FE-0BFC-4F7A-B68B-FF5DC8BA1369

Q38019790-2B5AF973-5E05-458D-A122-B2888CFBA430

Q38019790-2BC6116B-9FAB-44AE-BE13-2749C592D1DF

Q38019790-2F4F85DE-580E-49F9-97B0-C70F387BB50E

Q38019790-33A4E3FD-A43F-42CA-9F0E-B7A8986531AD

Q38019790-347013B6-2757-4DCD-85D2-E67EA3898AC0

P304

Q38019790-63FAC14D-6835-4F98-B393-55F678268FEB

P31

Q38019790-28FD0F34-15B0-46B6-BAD4-F4C272FAF901

P356

Q38019790-23434989-C442-455D-9195-41F6376402EB

P433

Q38019790-85A504C9-C6DD-410A-9174-708A4DEB414C

P478

Q38019790-AA6A8B9B-4A3C-4A3C-B5F0-70F6515CF4C4

P577

Q38019790-4E6156AF-1D09-4A77-9CB9-E5227880D2E5

P698

Q38019790-F9AC6D4C-BC6F-45CC-B63E-96743C61A2ED

P356

107327481201900304

P1433

P1476

Radioimmunotherapy for B-cell non-hodgkin lymphomas.

@en

P2093

Michael Tomblyn

http://www.w3.org/2001/XMLSchema#string

P2860

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.

Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.

A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.

A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.

Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.

Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.

A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.

Regulation of CD20 expression by radiation-induced changes in intracellular redox status.

P304

196-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/107327481201900304

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22710895

http://www.w3.org/2001/XMLSchema#string